ARTICLE | Finance
Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more
By Paul Bonanos, Director of Biopharma Intelligence
December 5, 2024 9:46 PM UTC
After seven years subsisting on seed capital, Antag has attracted a series A round that will support clinical testing of a GIPR antagonist, the first human test of a thesis that a standalone peptide aimed at that target can become a useful tool in an evolving marketplace for obesity therapies.
Versant Ventures, which is building a portfolio of obesity therapies that Managing Director Alex Mayweg called its “Beyond Ozempic” strategy, led the €80 million ($83.9 million) for Copenhagen-based Antag Therapeutics ApS…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654388/broadening-versant-s-obesity-portfolio-antag-plots-clinical-path-with-80m